

OptumRx has partnered with CoverMyMeds to receive prior authorization requests, saving you time and often delivering real-time determinations.

Visit go.covermymeds.com/OptumRx to begin using this free service.

Please note: All information below is required to process this request.

Mon-Fri: 5am to 10pm Pacific / Sat: 6am to 3pm Pacific

Epogen® Prior Authorization Request Form (Page 1 of 3) DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)				Provider Information (required)				
Member Name:			Provider Name:					
Insurance ID#:			NPI#:	NPI#: Specialty:				
Date of Birth:			Office Phone:	Office Phone:				
Street Address:			Office Fax:					
City:	State:	Zip:	Office Street Addres	Office Street Address:				
Phone:			City:	State:	Zip:			
		Medication Ir	nformation (require	·d)				
Medication Name:			Strength:					
☐ Check if requesting brand			Directions for Use:					
☐ Check if request is		therapy						
		Clinical Info	ormation (required)					
Select the diagnos	sis below:		(,)					
☐ Anemia due to her		treatment						
☐ Anemia in cancer	,							
Anemia in chronic								
□ Anemia in HIV-infe	ected patients							
□ Anemia in myelod								
-	_	eneic blood transfusion in	n patients undergoing sur					
Other diagnosis: ICD-10 Code(s):								
Clinical Information:								
Is the patient on dialy								
•	ū	sease (ESRD)? U Yes						
payment to manage t	he patient's ESRD o	are? 🗆 Yes 🗆 No	•	center) receiv	ring a monthly capitation			
Has the patient been evaluated for adequate iron stores? Yes No								
Select if the patient has history of failure, contraindication, or intolerance to the following: Aranesp Procrit								
For anemia due to h	epatitis C virus (Ho	CV) treatment, also ans	wer the following:					
Does the patient have a diagnosis of hepatitis C virus (HCV) infection?								
Please provide the hemoglobin (Hgb) and hematocrit (Hct) levels collected within 30 days of this request:								
Hgb:	g/dL Hct:	% Date:						
Select if the patient is Ribavirin Interferon alfa	-	ing:						
☐ Peg-interferon a Reauthorization:	ıııa							
	v hemoglobin (Hab)	and hematocrit (Hct) leve	els collected over a 3 mo	nth period:				
		% Date:						
-	-	% Date:						
_	-	% Date:						
		ed for blood transfusion? ased by 1 g/dL or more fr	rom pre-treatment level?	□ Yes □ N	0			



Epogen® Prior Authorization Request Form (Page 2 of 3) DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

For anemia in cancer patients on chemotherapy, also answer the following:								
Have all other causes of anemia been ruled out? \(\bar{\text{Ves}} \) No								
Please provide the hemoglobin (Hgb) and hematocrit (Hct) levels collected within 2 weeks of this request:								
Hgb: g/dL Hct: % Date:								
Is the patient's cancer a non-myeloid malignancy? Yes No								
Is the patient concurrently on chemotherapy? Yes No								
Will the patient be receiving concomitant chemotherapy for a minimum of 2 months? ☐ Yes ☐ No								
Is the anemia caused by the cancer chemotherapy?								
Please provide the hemoglobin (Hgb) and hematocrit (Hct) levels collected within 2 weeks of this request:								
Hgb: g/dL Hct: % Date:								
Has the patient had a decrease in the need for blood transfusion?								
Has the patient's hemoglobin (Hgb) increased by 1 g/dL or more from pre-treatment level? ☐ Yes ☐ No Is the patient currently on chemotherapy? ☐ Yes ☐ No								
Will the patient be receiving concomitant chemotherapy for a minimum of 2 months? Yes No								
Is the anemia caused by the cancer chemotherapy?								
For anemia in chronic kidney disease (CKD) , also answer the following:								
Please provide the hemoglobin (Hgb) and hematocrit (Hct) levels collected within 30 days of this request:								
Hgb: g/dL Hct: % Date:								
Does the rate of hemoglobin decline indicate the likelihood of requiring a red blood cell (RBC) transfusion?								
Is reducing the risk of alloimmunization and/or other RBC transfusion-related risks a goal? Yes No								
Reauthorization:								
Is the patient on dialysis? ☐ Yes ☐ No								
Does the patient have end-stage renal disease (ESRD)?								
Document the monthly hemoglobin (Hgb) and hematocrit (Hct) levels collected over a 3 month period:								
Hgb: g/dL Hct: % Date:								
Hgb: g/dL Hct: % Date:								
Hgb: g/dL Hct: % Date:								
Has the patient had a decrease in the need for blood transfusion? Yes No								
Has the patient's hemoglobin (Hgb) increased by 1 g/dL or more from pre-treatment level? Yes No								
Has the patient been evaluated for adequate iron stores? ☐ Yes ☐ No								
For anemia in HIV-infected patients, also answer the following:								
Please provide the hemoglobin (Hgb) and hematocrit (Hct) levels collected within 30 days of this request:								
Hgb: g/dL Hct: % Date:								
Is the serum erythropoietin level 500 mU/mL or less? Yes No								
Does the patient have a diagnosis of HIV infection? ☐ Yes ☐ No								
Is the patient receiving zidovudine (AZT) therapy?								
Reauthorization:								
Document the monthly hemoglobin (Hgb) and hematocrit (Hct) levels collected over a 3 month period:								
Hgb: g/dL Hct: % Date:								
Hgb: g/dL Hct: % Date:								
Hgb: g/dL Hct: % Date:								
Has the patient had a decrease in the need for blood transfusion?								
Has the natient's hemoglobin (Hgh) increased by 1 g/dl, or more from pre-treatment level? — Yes — No.								



Epogen® Prior Authorization Request Form (Page 3 of 3) DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

For anemia in	myelodysplastic syndr	ome (MDS) , also ansv	ver the following:				
Does the patie	ent have a serum erythrop	oietin level of 500 mU/m	nL or less? Yes No				
Does the patie	ent have transfusion-depe	ndent MDS? 🛚 Yes 🕻	l No				
Reauthorizati	on:						
Document the	monthly hemoglobin (Hgl	o) and hematocrit (Hct)	levels collected over a 3 month peri	od:			
Hgb:	g/dL Hct:	% Date:					
Hgb:	g/dL Hct:	% Date:					
Hgb:	g/dL Hct:	% Date:					
Has the patien	t had a decrease in the n	eed for blood transfusio	n? 🗆 Yes 🗀 No				
Has the patien	t's hemoglobin (Hgb) incr	eased by 1 g/dL or mor	e from pre-treatment level? \(\sigma\) Yes	□ No			
For preoperat	tive use for reduction of	allogeneic blood tran	sfusion in patients undergoing su	rgery, also answer the following:			
Is the patient s	scheduled to undergo elec	tive, non-cardiac, or no	n-vascular surgery? 🛭 Yes 🔲 No				
Is the hemoglobin (Hgb) greater than 10 g/dL to less than or equal to 13 g/dL?							
Is the patient a	at high risk for perioperativ	re transfusions? ☐ Yes	, □ No				
Is the patient u	unwilling or unable to dona	ate autologous blood pre	e-operatively?				
Are there any oth this review?	her comments, diagnoses,	symptoms, medications	tried or failed, and/or any other inforn	nation the physician feels is important to			
Please note:		nied unless all required info		call 1_800_711_4555			
<u>Please note</u> :		•	rmation is received. prior authorization requirements, please	call 1-800-711-4555.			

For urgent or expedited requests please call 1-800-711-4555.

This form may be used for non-urgent requests and faxed to 1-800-527-0531.